



Cyto Pulse Sciences, Inc.

Glen Burnie, MD, USA
Voice: 410-787-1890
www.cytopulse.com

Contact: Tim Hurd

FOR IMMEDIATE RELEASE

December 23, 2008

Cyto Pulse Sciences as Presenter, Sponsor and Exhibitor at the DNA Vaccines 2008 Conference in Las Vegas

GLEN BURNIE, MD., December 23, 2008 -- Cyto Pulse Sciences, a leading producer of electric field based, intradermal DNA Vaccine delivery systems, presented new research data on genetic vaccines delivered with its patented electroporation system, Derma Vax™, at the DNA Vaccines conference in Las Vegas, NV from 09-11 December 2008.

Manager of EU Operations, Dr. Anna-Karin Roos, presented new pre-clinical data on several vaccine projects and reported on the progress of ongoing and upcoming clinical trials in the Cyto Pulse pipeline. The presentation “Skin Electroporation - An Effective and Tolerable Approach to DNA Vaccination in Patients” included recent advances in making the Cyto Pulse electroporation system, Derma Vax™, highly tolerable for patients.

Dr. Roos also presented a poster “Antigen expression, DNA persistence and gene profiling after intradermal DNA electrovaccination” with data from her last project as a post-doc at the Karolinska Institutet, Sweden. The International Society of DNA Vaccines awarded Dr. Roos the Dr. Maurice Hilleman DNA Vaccine Award for her research, “in recognition for outstanding achievements in the field of DNA-mediated immunization”.

Four additional posters by Karolinska Institutet researchers showed promising pre-clinical data on DNA vaccines delivered with the Derma Vax™ system. Dr Andreas Bråve from the Karolinska Institutet complemented his work with a presentation titled “Experimental and Clinical Approaches for Genetic Immunization against HIV-1”. In his talk he described the improvement in immune response they have seen when enhancing delivery of their vaccine with Derma Vax™ electroporation. He also described their next clinical trial where the HIV vaccine will be delivered with Cyto Pulse’s Derma Vax™.

Furthermore, Dr. Alan King, a Cyto Pulse Vice President, co-chaired the session “Late Breaker Session Selected from Oral Submissions” and participated in a Corporate Roundtable discussion entitled “What’s Next for DNA Vaccines?” The discussion was focused around the current challenges of DNA vaccine development and also highlighted the overall business outlook for the industry in the next years to come.

Cyto Pulse was a presenter, exhibitor and sponsor at the conference and Richard Walters, Cyto Pulse President said, “It was a very significant opportunity for Cyto Pulse to exchange information with the DNA Vaccine community on the advancement of the technology”.



About Cyto Pulse Sciences

Cyto Pulse Sciences, Inc. is a biomedical device and treatment development company commercializing innovative technology to produce and deliver new therapeutics for cancer treatments (immunotherapy), protection against infectious diseases (prophylaxis therapy), and correcting genetic defects (gene therapy). Cyto Pulse technology is used in a wide range of fields including monoclonal antibody discovery, polynucleotide vaccine production, and delivery of polynucleotide (DNA/RNA) vaccines. Additional information on Cyto Pulse is available at the company's website, <http://www.cytopulse.com>.

###